Seroprevalence of Hepatitis B Viral Markers Among Freshmen — 20 Years After Mass Hepatitis B Vaccination Program in Taiwan
Article Outline
Background/Purpose
The nationwide hepatitis B vaccination program in Taiwan was well known for its efficacy in reducing the carrier rate of hepatitis B and the morbidity and mortality of hepatitis B-related diseases among children. The aim of this study was to investigate the seroprevalence of hepatitis B 20 years after this program was implemented.
Methods
A total of 7592 freshmen from one university in Northern Taiwan participated in this study during their school entry health exam in September 2003 and September 2004. Basic data including gender, birthday, family history and vaccination history of hepatitis B by self-reported questionnaire were collected. Hepatitis B serum markers, including hepatitis B surface antigen, antibody against hepatitis B surface antigen, and antibody against hepatitis B core antigen were all checked. The differences in the seroprevalence of hepatitis B between two groups of subjects born before July 1984 and after July 1984 were examined. Multiple logistic analyses were performed for identifying the odds ratio (OR) of family history and other variables for each hepatitis B serum marker.
Results
Subjects born after July 1984 were found to have a lower rate of hepatitis B surface antigen of 2.2% (95% confidence interval [CI], 1.8–2.6%) vs. 7.4% (95% CI, 5.9–8.9%), and core antibody against hepatitis B of 6.7% (95% CI, 6.0–7.3%) vs. 23.5% (95% CI, 21.1–25.9%), but a higher rate of surface antibody against hepatitis B of 74.3% (95% CI, 73.2–75.4%) vs. 69.1% (95% CI, 66.5–71.7%) compared with those born before July 1984 (all p < 0.001). Subjects with a family history of hepatitis B had higher risk of being infected by hepatitis B (OR, 4.07; 95% CI, 3.18–5.12) and becoming carriers (OR, 7.26; 95% CI, 5.05–10.44) after adjustment for sex, age, birth year, and self-reported hepatitis B vaccination history.
Conclusion
The seroprevalence of hepatitis B surface antigen continued to decline 20 years after neonatal hepatitis B vaccination program. It is strongly recommended that those who have a family history of hepatitis B should receive early check-up of hepatitis B status after complete vaccination or closely follow up their hepatitis B status after neonatal hepatitis B vaccination.
Key Words: hepatitis B , seroprevalence , Taiwan , vaccination , youth
No full text is available. To read the body of this article, please view the PDF online.
References
- . Hepatitis B virus infection in Taiwan . N Engl J Med . 1977;297:668–669
- . A seroepidemiologic study of hepatitis B virus infection in Taiwan . Taiwan Yi Xue Hui Za Zhi . 1978;77:908–918
- Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis . Cancer . 1991;68:1737–1741
- Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan . Lancet . 1981;2:1129–1133
- Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma . Cancer . 1989;64:2377–2380
- Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers . JAMA . 1988;260:2231–2235
- A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers . JAMA . 1987;257:2597–2603
- Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization . J Infect Dis . 1999;179:367–370
- Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan . JAMA . 1996;276:906–908
- Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group . N Engl J Med . 1997;336:1855–1859
- Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination . Hepatology . 2004;39:58–63
- Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan . J Pediatr . 2001;139:349–352
- Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination . Ann Intern Med . 2001;135:796–800
- Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan . J Med Virol . 2003;69:471–474
- Hepatitis B virus infection in adolescents in a rural township–15 years subsequent to mass hepatitis B vaccination in Taiwan . Vaccine . 2005;24:759–765
- Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched . Epidemiol Rev . 2006;28:126–135
- Changes of hepatitis B markers among young adults in a hepatitis B virus endemic area: a follow up study on medical students . Kaohsiung J Med Sci . 1997;13:286–292
- . A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children . Hepatology . 1988;8:1130–1133
- Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants . Vaccine . 2005;23:4158–4166
- . Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? . J Gastroenterol Hepatol . 2005;20:5–10
- Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination . Hepatology . 2004;40:1415–1420
- Prevention of perina-tally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine . Lancet . 1983;2:1099–1102
- Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers . J Infect Dis . 1985;152:817–822
- Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan . Hepatogastroenterology . 1985;32:65–68
PII: S0929-6646(07)60001-1
doi:10.1016/S0929-6646(07)60001-1
© 2007 Formosan Medical Association & Elsevier. Published by Elsevier Inc. All rights reserved.
